Cancer News and Research

Latest Cancer News and Research

Geron's GRNOPC1 Phase 1 trial results on spinal cord injury presented at international conferences

Geron Corporation today announced two presentations on the company's ongoing Phase 1 clinical trial of the human embryonic stem cell-based therapy, GRNOPC1, in patients with spinal cord injury.

7 Jun 2011

Merck, Roche partner to develop cancer diagnostic assays

Merck, known outside the United States and Canada as MSD, and Roche today announced that they have entered into a collaboration focused on the application and development of diagnostic assays for use with Merck's investigational cancer therapy portfolio.

From Roche Sequencing and Life Science 7 Jun 2011

IsoRay completes Iotrex license agreement with Dr. Reddy's

IsoRay, Inc. announced today that it has completed a license agreement with Dr. Reddy's Laboratories for exclusive worldwide licensing rights to Iotrex, a liquid iodine radiation, for use in brain cancer treatment.

7 Jun 2011

OncoSec announces additional evaluation of ElectroImmunotherapy Phase I trial on melanoma

OncoSec Medical Incorporated, which is developing its advanced-stage ElectroOncology therapies to treat solid tumor cancers, announced today that additional evaluation of a previous Phase I trial provided further evidence that a DNA plasmid encoded to produce IL-12 delivered by electroporation into melanoma lesions induces responses to known and novel antigens, resulting in regression of local treated lesions as well as distant untreated lesions.

7 Jun 2011

Simcere announces settlement agreement with former Jiangsu Quanyi shareholders

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced that a settlement agreement with certain former shareholders and directors of Jiangsu Quanyi Biological Technology Stock Co., Ltd. has become effective.

7 Jun 2011

DxTerity acquires intellectual property rights to blood based genomic testing from SourceMDx

DxTerity Diagnostics announced today that it has acquired intellectual property rights to several blood based cancer diagnostic tests from SourceMDx Inc.

7 Jun 2011

Intrexon, Halozyme partner to develop subcutaneous alpha 1-antitrypsin for A1AT deficiency

Halozyme Therapeutics, Inc. and Intrexon Corporation, today announced the signing of a worldwide exclusive licensing agreement for the use of rHuPH20 in the development of a subcutaneous injectable formulation of Intrexon Corporation's recombinant human alpha 1-antitrypsin (rHuA1AT).

7 Jun 2011

ABRAXANE and bevacizumab clinical studies on unresectable melanoma presented at ASCO 2011

Celgene International Sàrl today announced that results from two investigator initiated studies including ABRAXANE, and bevacizumab in unresectable melanoma were presented at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, IL.

7 Jun 2011

Moving Met molecules from inside to outside of the cell could halt cancer growth

Work by researchers at Queen Mary, University of London could point to a new way to treat aggressive types of cancer.

7 Jun 2011

Unique clinical trial addresses important questions about treating AIDS-related cancers

As the world marks the 30-year anniversary of the first reporting of HIV/AIDS, now comes the realization of a new challenge for people with the incurable disease. For reasons not yet clear, people with HIV face a higher rate of cancers not usually associated with HIV. This increasing rate of "non-AIDS defining cancers" includes lung, head and neck, liver, kidney, and anal cancers, among others.

7 Jun 2011

Dacogen Phase III study results on acute myeloid leukemia presented at ASCO 2011

Results from the DACO-016 trial of Dacogen (decitabine) in acute myeloid leukemia (AML) were presented today at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO)

7 Jun 2011

Renewal Project receives Palo Alto City Council's certification to rebuild, expand Stanford Hospitals

The Palo Alto City Council today voted unanimously to certify the Final Environmental Impact Report (FEIR), grant land use approvals and execute a Development Agreement with Stanford Hospital & Clinics, Lucile Packard Children's Hospital and Stanford University, including a $175 million community benefits package as part of the Renewal Project.

7 Jun 2011

Ligand's LGD-4033 Phase I clinical trial data presented at the Endocrine Society annual meeting

Ligand Pharmaceuticals Incorporated today announced that data from a comprehensive Phase I multi-dose program with its selective androgen receptor modulator (SARM) LGD-4033 was featured in a poster presentation today at the Endocrine Society Annual Meeting in Boston, June 4-7, 2011.

7 Jun 2011

FDA lifts BioSante's GVAX Prostate Cancer Vaccine clinical hold

BioSante Pharmaceuticals, Inc. today announced that the FDA's clinical hold on the GVAX Prostate Cancer Vaccine for the treatment of prostate cancer has been lifted by FDA.

7 Jun 2011

Independent investigators report Lymphoseek meets all endpoints in NEO3-09 Phase 3 study

Independent investigators reported today full results from the NEO3-09 study, reaffirming earlier top-line results that showed Lymphoseek met all primary and secondary endpoints and exhibited superior performance to vital blue dye in intraoperative lymphatic mapping (ILM) procedures.

7 Jun 2011

Increased blood clotting tendency linked to elevated bowel cancer risk

Back in the mid 19th century, a French doctor, Armand Trousseau, discovered a connection between cancer and thrombosis - the formation of often dangerous blood clots that can lead to venous occlusion.

7 Jun 2011

Initial positive results from ZIOPHARM's ZIN-CTI-001 Phase Ib study against advanced melanoma

ZIOPHARM Oncology, Inc. announced today that Douglas J. Schwartzentruber, MD, FACS, of the Indiana University Health Goshen Center for Cancer Care, presented initial positive clinical results from the first-ever treatment demonstrating control over transgene encoding of a therapeutic anticancer protein in humans using a small molecule activator ligand.

7 Jun 2011

Study finds decline in low-severity visits after implementation of Massachusetts health care law

While overall emergency department use in Massachusetts continues to rise, the number of low-severity visits dropped slightly since the implementation of the state's health care reform law, according to an Annals of Emergency Medicine study published online.

7 Jun 2011

Celgene announces ABRAXANE plus gemcitabine, bevacizumab phase II trial data on breast cancer

Celgene International Sàrl today announced that results from an investigator-initiated phase II study of ABRAXANE, gemcitabine and bevacizumab as first-line treatment in metastatic breast cancer were presented at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, IL.

7 Jun 2011

New poll finds 63% of Massachusetts residents support health care law enacted in 2006

A new poll by the Harvard School of Public Health and The Boston Globe finds 63% of Massachusetts residents support the health care reform legislation enacted in 2006, 21% oppose it while 6% are not sure and 9% have not heard or read about the law.

7 Jun 2011

Cancer News and Research

Latest Cancer News and Research

Geron's GRNOPC1 Phase 1 trial results on spinal cord injury presented at international conferences

Merck, Roche partner to develop cancer diagnostic assays

IsoRay completes Iotrex license agreement with Dr. Reddy's

OncoSec announces additional evaluation of ElectroImmunotherapy Phase I trial on melanoma

Simcere announces settlement agreement with former Jiangsu Quanyi shareholders

DxTerity acquires intellectual property rights to blood based genomic testing from SourceMDx

Intrexon, Halozyme partner to develop subcutaneous alpha 1-antitrypsin for A1AT deficiency

ABRAXANE and bevacizumab clinical studies on unresectable melanoma presented at ASCO 2011

Moving Met molecules from inside to outside of the cell could halt cancer growth

Unique clinical trial addresses important questions about treating AIDS-related cancers

Dacogen Phase III study results on acute myeloid leukemia presented at ASCO 2011

Renewal Project receives Palo Alto City Council's certification to rebuild, expand Stanford Hospitals

Ligand's LGD-4033 Phase I clinical trial data presented at the Endocrine Society annual meeting

FDA lifts BioSante's GVAX Prostate Cancer Vaccine clinical hold

Independent investigators report Lymphoseek meets all endpoints in NEO3-09 Phase 3 study

Increased blood clotting tendency linked to elevated bowel cancer risk

Initial positive results from ZIOPHARM's ZIN-CTI-001 Phase Ib study against advanced melanoma

Study finds decline in low-severity visits after implementation of Massachusetts health care law

Celgene announces ABRAXANE plus gemcitabine, bevacizumab phase II trial data on breast cancer

New poll finds 63% of Massachusetts residents support health care law enacted in 2006

Understanding the DNA Damage Response in Innate Immunity eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in